# Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine

> **NCT02222870** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 60 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Fluzone® Quadrivalent Influenza Vaccine, No Preservative
- **BIOLOGICAL:** Fluzone® Quadrivalent Influenza Vaccine, No Preservative

## Key facts

- **NCT ID:** NCT02222870
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2014-12
- **Final completion:** 2015-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2015-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02222870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02222870, "Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02222870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*